BofA analyst Travis Steed raised the firm’s price target on Becton Dickinson (BDX) to $207 from $190 and keeps a Neutral rating on the shares as the firm moves the valuation year out one year to reflect the calendar change while highlighting its medtech picks for 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson, University of Pennsylvania partner on human immune profiling
- Becton Dickinson price target raised to $210 from $202 at RBC Capital
- Becton Dickinson announces expansion of BD MAX System menu
- Roth Capital healthcare analyst holds an analyst/industry conference call
- Unusually active option classes on open December 4th